-
INTERPROVINCIAL DISPARITIES IN ACCESS TO DERMATOLOGY TREATMENTS IN CANADA
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF BIOLOGIC THERAPIES FOR SEVERE ASTHMA: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
THE COST-EFFECTIVENESS OF INCLUSION OF JERYL LYNN MUMPS VACCINE IN THE MEASLES-RUBELLA ROUTINE IMMUNISATION SCHEDULE AMONG CHILDREN IN INDIA
Mar 18, 2026, 21:38 PM -
COMPARING SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2I) VERSUS RENIN-ANGIOTENSIN SYSTEM INHIBITOR (RASI) IN HEART FAILURE PATIENTS WITH ALZHEIMER’S DISEASE AND RELATED DEMENTIA (ADRD)
Mar 18, 2026, 21:38 PM -
EFFICACY AND MARKET SHARE OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS FOR CURRENT OFF-LABEL USES: A TARGETED LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
HEALTH RELATED QUALITY OF LIFE IN ULCERATIVE COLITIS: A SYSTEMATIC EVALUATION OF INSTRUMENTS AND THEIR PSYCHOMETRIC VALIDATION
Mar 18, 2026, 21:38 PM -
AN ALGORITHM TO IDENTIFY LESS INVASIVE SURFACTANT ADMINISTRATION USING A REAL-WORLD DATABASE OF PRETERM INFANTS
Mar 18, 2026, 21:38 PM -
CLINICAL VALIDATION OF A MACHINE-LEARNING-ENRICHED IMMUNE-MEDIATED NECROTIZING MYOPATHY COHORT USING LINKED LABORATORY AND CLAIMS DATA
Mar 18, 2026, 21:38 PM -
FACTORS ASSOCIATED WITH HEALTHCARE COSTS AND DISEASE PROGRESSION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS IN THE US REAL-WORLD SETTING
Mar 18, 2026, 21:38 PM -
ASSOCIATION OF MARIJUANA USE AND HEALTH-RELATED QUALITY OF LIFE AMONG CARDIOVASCULAR DISEASE PATIENTS. EVIDENCE FROM THE BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM
Mar 18, 2026, 21:38 PM -
DIGITAL TOOL FOR TECHNICAL EVALUATION OF SINGLE-USE MEDICAL DEVICES IN MERCOSUR PUBLIC PROCUREMENT
Mar 18, 2026, 21:38 PM -
PROMISE OF REAL-WORLD DATA NETWORKS: INNOVATIONS IN TRIAL DESIGN USING PCORNET®
Mar 18, 2026, 21:38 PM -
REAL-WORLD INSIGHTS ON CONTROLLED OVARIAN STIMULATION FOR IVF/ICSI: DATA FROM A LARGE FERTILITY EMR DATABASE IN THE US (2010 - 2024)
Mar 18, 2026, 21:38 PM -
TRIALMAP: AN END-TO-END SOLUTION FOR MODERN CLINICAL TRIALS DESIGN WITH RWD AND AI
Mar 18, 2026, 21:38 PM -
CONTENT VALIDITY OF THE EQ-HWB-9 IN PATIENTS WITH ADVANCED ILLNESSES: A COGNITIVE DEBRIEFING STUDY
Mar 18, 2026, 21:38 PM -
COMPARATIVE POST-MARKETING SAFETY STUDY OF NIRSEVIMAB AND PALIVIZUMAB: A PHARMACOVIGILANCE ANALYSIS USING FAERS AND WHO VIGIACCESS
Mar 18, 2026, 21:38 PM -
EQ-5D BASED UTILITY VALUES BY CLINICAL RESPONSE AND SYMPTOM SEVERITY IN JAPANESE PATIENTS WITH MAJOR DEPRESSIVE DISORDER: POST-HOC ANALYSIS OF JAPANESE BREXPIPRAZOLE CLINICAL TRIALS
Mar 18, 2026, 21:38 PM -
INTEGRATING GENERATIVE ARTIFICIAL INTELLIGENCE (AI) INTO BIOSTATISTICAL WORKFLOWS FOR TRIAL EMULATION: A FRAMEWORK TO ACCELERATE REAL-WORLD EVIDENCE GENERATION
Mar 18, 2026, 21:38 PM -
PCV20 FOR HIGH-RISK POPULATIONS: A COST-UTILITY ANALYSIS FROM THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE
Mar 18, 2026, 21:38 PM -
IMPACT OF LUPUS NEPHRITIS FLARES ON HEALTHCARE UTILIZATION: A RETROSPECTIVE COHORT STUDY IN THE UNITED STATES BETWEEN 2016 AND 2025
Mar 18, 2026, 21:38 PM
